Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ST-alphaDC1
- Development stage
- Phase 2
- Lead developer
- Roswell Park Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
ST-alphaDC1 is a cell-based treatment utilizing autologous alpha-type-1 polarized dendritic cells. These cells are engineered by treating dendritic cells (DCs) with interferon-alpha (IFN-a) and polyinosinic:polycytidylic acid (p-I:C) in addition to a cytokine cocktail (tumor necrosis factor alpha/Interleukin-1beta/IFN-gamma). This process produces mature, potent immunostimulating alphaDC1 cells that exhibit high responsiveness to lymphoid chemokines and produce high levels of interleukin-12p70 (IL-12p70). When pulsed with specific tumor-associated antigens (TAAs), ST-alphaDC1 is capable of inducing a potent cytotoxic T-lymphocyte (CTL) response against these TAAs, making it suitable for use as a cancer vaccine. It is being investigated for the treatment of melanoma.
- Other names
- alpha-type-1 polarized dendritic cellsalpha-type1 polarized dendritic cellsalpha-type 1 polarized dendritic cellsautologous alphaDC1 vaccine
Beyond the preview
Go deeper on ST-alphaDC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ST-alphaDC1.